New L-dopa codrugs as potential antiparkinson agents

Archiv der Pharmazie

Volumn 341, Issue 7, 2008, Pages 412-417

  Sozio, Piera ^a   Iannitelli, Antonio ^a   Cerasa, Laura Serafina ^a   Cacciatore, Ivana ^a   Cornacchia, Catia ^a   Giorgioni, Gianfabio ^b   Ricciutelli, Massimo ^b   Nasuti, Cinzia ^b   Cantalamessa, Franco ^b   Di Stefano, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Caffeic acid; Carnosine; L dopa; L dopa codrugs; Parkinson's disease

Indexed keywords

3,4 DIACETYLOXY LEVO DOPA METHYL ESTER CAFFEIC ACID CONJUGATE; CAFFEIC ACID; CARNOSINE; DOPAMINE; GLUTATHIONE PEROXIDASE; LEVODOPA; N ACETYL 3,4 DIACETYLOXY LEVO DOPA CARNOSINE METHYL ESTER CONJUGATE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ANTIOXIDANT; ANTIPARKINSON AGENT; CAFFEIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; ANTIPARKINSON AGENTS; CAFFEIC ACIDS; CARNOSINE; CORPUS STRIATUM; DOPAMINE; GLUTATHIONE PEROXIDASE; LEVODOPA; PARKINSON DISEASE; RATS; SUPEROXIDE DISMUTASE;

EID: 52449092612     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700228     Document Type: Article

References (24)

1. D. G. Graham, Mol. Pharmacol. 1978, 14, 633-643.
2. A. Di Stefano, P. Sozio, A. Cocco, A. Iannitelli, et al., J. Med. Chem. 2006, 49, 1486-1493.
3. F. Pinnen, I. Cacciatore, C. Cornacchia, P. Sozio, et al., J. Med. Chem. 2007, 50, 2506-2515.
4. J. P. Ley, H. J. Bertram, J. Agric. Food Chem. 2003, 51, 4596-4602.
5. R. Kohen, Y. Yamamoto, K. C. Cundy, B. N. Ames, Proc. Natl. Acad. Sci. USA 1988, 85, 31753179.
6. S. D. Marchis, C. Modena, P. Peretto, A. Migheli, et al., Biochemistry 2000, 65, 824-833.
7. A. N. Fonteh, R. J. Harrington, A. Tsai, P. Liao, M. G. Harrington, Amino Acids 2007, 32, 213-224.
8. J. E. Preston, A. R. Hipkiss, D. T. Himsworth, I. A. Romero, J. N. Abbott, Neurosci. Lett. 1998, 242, 105-108.
9. J. H. Kang, K. S. Kim, S. Y. Choi, H. Y. Kwon, et al., Biochim. Biophys. Acta 2002, 1570, 89-96.
10. A. Boldyrev, R. Song, D. Lawrence, D. O. Carpenter, Neuroscience 1999, 94, 571-577.
11. N. Bodor, K. B. Sloan, T. Higuchi, K. Sasahara, J. Med. Chem. 1977, 20, 1435-1445.
12. S. H. Park, S. H. Kang, S. H. Lim, H. S. Oh, K. H. Lee, Bioorg. Med. Chem. Lett. 2003, 13, 3455-3459.
13. C. Chavis, F. Grodenic, J.-L. Imbach, Eur. J. Med. Chem. 1981, 16, 219-227.
14. D. J. W. Grant, T. Higuchi in Solubility behaviour of organic compounds, Wiley, New York, 1990, pp. 164-175.
15. W. H. Streng in Characterization of Compounds in Solution - Theory and practice, Kluver Academic Plenum Publisher, New York, 2001, pp.161-180.
16. N. S. Teuscher, R. F. Keep, D. E. Smith, Pharmaceut. Res. 2001, 18, 807-813.
17. R. Kohen, Y. Yamamoto, K. C. Cundy, B. N. Ames, Proc. Natl. Acad. Sci. USA 1988, 85, 3175-3179.
18. U. Gundert-Remy, R. Hildebrand, A. Stiehl, E. Weber, et al., Eur. J. Clin. Pharmacol. 1983, 25, 69-72.
19. M. Da Prada, H. H. Keller, L. Pieri, L. Kettler, W. E. Haefely, Experientia 1984, 40, 1165-1172.
20. C. Nasuti, R. Gabbianelli, M. L. Falcioni, A. Di Stefano, et al., Toxycology 2007, 229, 194-205.
21. C. Michiels, M. Raes, O. Topussaint, J. Remacle, Free Radic. Biol. Med. 1994, 17, 235-248.
22. A. J. Nappi, E. Vass, Biochim. Biophys. Acta 1997, 1336, 295-301.
23. U. J. Jung, M. K. Lee, Y. B. Park, S. M. Jeon, M. S. Choi, J. Pharmacol. Exp. Ther. 2006, 318, 476-483.
24. M. A. Babizhayev, M. C. Seguin, J. Gueyne, R. P. Evstigneeva, et al., Biochem. J. 1994, 304, 509-516.